RTP On Demand: Current and Future Role of PARP Inhibitors in the Management of Ovarian Cancer (Video Program) - Video 18Differences in form, strength and number of pills or capsules administered per day among approved and investigational PARP inhibitors
1:53 minutes.
TRANSCRIPTION:
DR MATULONIS: There are going to be differences with the number of pills or capsules taken per day for niraparib versus rucaparib versus olaparib, although I think if SOLO-2 — we just heard about the results of SOLO-2 briefly in the press release, but that is using the tablet form of olaparib versus the capsule form. The tablets are 100 milligrams, so you take fewer tablets per day. It’s 300 twice daily as opposed to 400 twice daily. Rucaparib, that comes in, I believe, 300-milligram tablets. And the niraparib comes in 100-milligram tablets. So the tablets and how many pills patients take per day will be slightly different amongst those 3. DR LOVE: What’s the bottom line in terms of number of pills you take a day with the 3 drugs? DR MATULONIS: For right now for olaparib, using the capsule, it’s 16 capsules per day, because they come in 50-milligram capsules. However, the subsequent trials — SOLO-1, 2 and 3, are using the tablet formation. So that should be 3 tablets twice daily. DR LOVE: And is that available commercially? I mean, can you — DR MATULONIS: No, it’s not. It’s not available commercially. DR LOVE: But you’re saying, if it gets approved, then maybe they’ll start making these? DR MATULONIS: You got it. That’s correct. DR LOVE: And so right now, it’s 16 pills a day, could go down to 6. DR MATULONIS: Right. DR LOVE: Okay. And then what about the other two? DR MATULONIS: Niraparib is 100-milligram tablets. And that’s going to be 3 per day. That’s 300 milligrams dosed once daily. And then rucaparib is 600 milligrams twice daily. And I believe rucaparib is in 300-milligram tablets, so that would be 2 tablets twice daily. |